Back to today’s briefing

Story perspectives

FDA Approves Sanofi's Qfitlia: Hemophilia Breakthrough with Risks

3/29/2025

39 4

Summary

Story summary

Sanofi's groundbreaking therapy, Qfitlia (fitusiran), has received FDA approval for hemophilia A and B, set to launch on March 28, 2025. This innovative treatment, administered every two months, promises a remarkable 90% reduction in bleeding episodes. While it offers hope for all patients, it also comes with potential risks of blood clots and liver damage.

1 of 1

Story summary

Sanofi's groundbreaking therapy, Qfitlia (fitusiran), has received FDA approval for hemophilia A and B, set to launch on March 28, 2025. This innovative treatment, administered every two months, promises a remarkable 90% reduction in bleeding episodes. While it offers hope for all patients, it also comes with potential risks of blood clots and liver damage.